NCT04266756 - A Study of Selexipag in Healthy Male Participant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 23, 2020

Primary Completion Date

August 14, 2020

Study Completion Date

August 14, 2020

Conditions

Healthy

Interventions

DRUG

Selexipag matrix tablet

Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.

DRUG

Selexipag encapsulated pellets

Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.

DRUG

Selexipag Immediate-release (IR) tablet

Participants will receive Selexipag immediate-release tablet orally under fasted condition.

Trial Locations (1)

Clinical Pharmacology Unit, Merksem